Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023

Cost Effectiveness and Resource Allocation

Review

Danko Grujic¹  Hanyu Chang²  Jay Pan³  Lizheng Shi⁴  Hao Hu⁵  Mihajlo Jakovljevic⁶  Chao Guo⁷  Jin Hui⁸  Zhong Li⁹ 

[1]Clinic for Cardiac Surgery, University Clinical Center of Serbia, Belgrade, Serbia

[2]Department of Medical Insurance, The First Hospital of Lanzhou University, Lanzhou, China

[3]HEOA Group, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China

[4]School of Public Administration, Sichuan University, Chengdu, China

[5]Health Systems Analytics Research Center, Tulane University, New Orleans, USA

[6]Institute of Chinese Medical Sciences, University of Macau, Macao, SAR, China

[7]Institute of Comparative Economic Studies, Hosei University Faculty of Economics, Tokyo, Japan

[8]Department of Global Health Economics and Policy, University of Kragujevac, 34000, Kragujevac, Serbia

[9]Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, Saint Petersburg, Russian Federation

[10]Institute of Population Research, Peking University, Beijing, China

[11]School of Economics and Management, Zhejiang Sci-Tech University, Hangzhou, China

[12]School of Health Policy and Management, Nanjing Medical University, Nanjing, Jiangsu, China

关键词: Chinese health reform;    Standards;    Perspective;    Market;    Supply;    Demand;    Medical care;    Pharmaceuticals;    Medical devices;    Industry;    Manufacturing;    Insurance policy;   

DOI  :  10.1186/s12962-023-00461-9

 received in 2023-06-19, accepted in 2023-07-26,  发布年份 2023

来源: Springer

【 摘 要 】

Chinese health system remains the crucial one for understanding the wider healthcare landscape across the Global South and in particular the leading Emerging Markets. Purpose of our observation was to understand the inner dynamics of mainland Chinese health reforms adopting a lengthy time horizon. We have analysed the public reports and seminal evidence on Chinese of multiple waves of national health reforms taking place since 1980s in terms of medical care and pharmaceuticals provision and financing. Chinese international trade with ASEAN nations and wider South-East Asia is accelerating its growth after the recovery of trade routes. In terms of health sector this means that global demand and supply of medical goods, services and pharmaceuticals remains largely driven by Chinese domestic developments. Furthermore, Chinese domestic manufacturing and sales of decent quality medical devices and services have grown exponentially. Some temporary pitfalls and increasing in rural–urban inequalities in equity of access and affordability of medical care and pharmaceuticals did take place. Despite these difficulties to generate a balanced development strategy for the largest global market, this is a clear path upwards. Further upcoming improvements expanding health insurance coverage are in strong demand for certain layers of the society. Domestic bottleneck weaknesses yet remain manufacturing, import and market penetration of cutting-edge pharmaceuticals such as monoclonal antibodies and targeted oncology agents. Yet some of these obstacles are likely to be overcome in foreseeable future with the adoption of responsible strategies by governmental agencies in health care arena.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

40517_2023_261_Article_IEq24.gif

13690_2023_1154_Article_IEq13.gif